VITRAKVI
These highlights do not include all the information needed to use VITRAKVI safely and effectively. See full prescribing information for VITRAKVI. VITRAKVI (larotrectinib) capsules, for oral use VITRAKVI (larotrectinib) oral solutionInitial U.S. Approval: 2018
9525f887-a055-4e33-8e92-898d42828cd1
HUMAN PRESCRIPTION DRUG LABEL
Dec 5, 2018
Loxo Oncology, Inc.
DUNS: 042572897
Products 3
Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.
LAROTRECTINIB
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
INGREDIENTS (3)
LAROTRECTINIB
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
INGREDIENTS (12)
LAROTRECTINIB
Product Details
FDA regulatory identification and product classification information